ArticleScientific reports2026
Protective effects of curcumin and resveratrol on neurodegeneration and cognitive dysfunction in a streptozotocin-induced alzheimer rat model.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by memory loss, cognitive decline, and behavioral disturbances. Given the limited efficacy of current treatments, there is an urgent need for new neuroprotective strategies. In this study, the therapeutic potential of curcumin and resveratrol was evaluated in a rat AD model induced by intracerebroventricular (ICV) administration of streptozotocin (STZ) (3 mg/kg). Subsequent to model induction, rats were administered curcumin, resveratrol, or a combination of both. The behavioral analyses, which included the Morris water maze, open field, and passive avoidance tests, revealed that both compounds significantly improved learning and memory performance. The histological and immunohistochemical findings demonstrated a decrease in caspase-3 and GFAP immunoreactivity, suggesting reduced neuronal apoptosis and astrocyte activation. The behavioral analyses, which included the Morris water maze, open field, and passive avoidance tests, revealed that both compounds significantly improved learning and memory performance. The histological and immunohistochemical findings demonstrated a decrease in caspase-3 and GFAP immunoreactivity, suggesting reduced neuronal apoptosis and astrocyte activation. Biochemical results showed an increase in total antioxidant status (TAS) and superoxide dismutase (SOD) activity, along with a decrease in total oxidative status (TOS) and TNF-α levels. Stereological evaluation also confirmed partial restoration of hippocampal volume. While curcumin and resveratrol exhibited potent neuroprotective effects when used separately, no synergistic interaction was observed when used in combination. These findings suggest that curcumin and resveratrol may serve as promising therapeutic agents for reducing oxidative stress, neuroinflammation, and neuronal degeneration associated with Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.